ArticleScience translational medicine2022
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.
Open access · goldAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 98 citations in OpenAlex.
- Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.The Journal of infectious diseases · 2026Trial
- A Single Dose Study of Pembrolizumab in People With HIV Infection Who are Immunologic Nonresponders.Open forum infectious diseases · 2026Trial
- Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.Signal transduction and targeted therapy · 2024Trial
- Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.Open forum infectious diseases · 2024Trial
- The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.Science advances · 2023Trial
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.Research square · 2026Article
- Article
- A novel antiviral strategy by disrupting the equilibrium of virus-host calcium homeostasis.Current opinion in virology · 2026Review
- Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.Nature medicine · 2026Article
- PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir.Nature medicine · 2026Article
- Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.Frontiers in immunology · 2026Review
- PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
- A novel diagnostic model for HIV-HTN comorbidity: genomic discovery, clinical validation, and mechanistic elucidation.Frontiers in medicine · 2026Article
- Comparison of manual and automated ultrasensitive assays for residual HIV-1 in plasma from individuals on suppressive antiretroviral therapy.Journal of clinical microbiology · 2025Article
- Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?Current opinion in HIV and AIDS · 2025Review
- HIV-1 accessory protein Vpr possesses a cryptic p300-dependent transcription-promoting activity that is blocked by histone deacetylases in CD4+ T cells.PLoS pathogens · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 4 countries.
Thomas S UldrickFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0001-6959-0924
Scott V AdamsFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-8411-8051
Remi FromentinDepartment of Microbiology, Infectiology, and Immunology, Université de Montréal and Centre de Recherche du CHUM, Montréal H2X0A9, Canada.ORCID 0000-0002-8153-1799
Michael RocheRMIT University, Melbourne, VIC 3083, Australia.ORCID 0000-0001-8819-0096
Steven P FlingFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0001-6263-0153
Priscila H GonçalvesHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Kathryn LurainHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-5794-7292
Ramya RamaswamiHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-5709-4675
Chia-Ching Jackie WangUniversity of California, San Francisco, San Francisco, CA 94110, USA.
Robert J GorelickAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-1773-9085
Jorden L WelkerAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Liz O'DonoghueFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-6296-2788
Harleen ChoudharyFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-0010-7556
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-9494-0268
Thomas A RasmussenDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.ORCID 0000-0001-5354-2442
Ajantha RhodesDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Carolin TumpachDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.ORCID 0000-0002-4851-652X
Robert YarchoanHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-3057-1395
Frank MaldarelliHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-3062-5250
Martin A CheeverFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-6892-4141
Rafick SékalyEmory University, Atlanta, GA 30322, USA.ORCID 0000-0002-7816-4828
Nicolas ChomontDepartment of Microbiology, Infectiology, and Immunology, Université de Montréal and Centre de Recherche du CHUM, Montréal H2X0A9, Canada.ORCID 0000-0001-9747-5018
Steven G DeeksUniversity of California, San Francisco, San Francisco, CA 94110, USA.ORCID 0000-0001-6371-747X
Sharon R LewinDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.ORCID 0000-0002-0330-8241
Fred Hutch Cancer Center · USNational Cancer Institute · USThe University of Melbourne · AUFrederick National Laboratory for Cancer Research · USCentre Hospitalier de l’Université de Montréal · CAUniversity of California, San Francisco · USEmory University · USUniversity of Washington · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MDelaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MCancer Immunotherapy Trials Network Central Operations and Statistical CenterUM1CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN · 2017 to 2022
$20.7MClinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6MHIV Persistence During Suppressive Antiretroviral TherapyZIABC011466 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALDARELLI, FRANK · 2012 to 2025
$16.0MClinical Interventional Studies of HIV ReservoirsZIABC011464 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALDARELLI, FRANK · 2012 to 2025
$13.2MTargeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman diseaseZIABC011954 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RAMASWAMI, RAMYA · 2020 to 2025
$3.8MDevelopment of Preventive Strategies and Therapy for HIV InfectionZIASC006737 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$3.0MPatient Oriented Research in Viral Malignancies and HIV-associated CancersZIABC011700 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2016 to 2017
$1.2MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC010888Intramural NIH HHS ZIA BC011700NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001ENCI NIH HHS UM1 CA154967NIAID NIH HHS UM1 AI126611
Abstract
In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent form where there is minimal transcription or protein expression. Latently infected cells are a major barrier to curing HIV. Increasing HIV transcription and viral production in latently infected cells could facilitate immune recognition and reduce the pool of infected cells that persist on ART. Given that programmed cell death protein 1 (PD-1) expressing CD4
Indexed as
HIV-1HIV InfectionsNeoplasmsAntibodies, Monoclonal, HumanizedCD4-Positive T-LymphocytesHumansPhylogenyProgrammed Cell Death 1 ReceptorRNAVirus LatencyAntibodies, Monoclonal, HumanizedpembrolizumabProgrammed Cell Death 1 ReceptorRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.